Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Required: CD20 positive by immunohistochemistry or flow cytometry after the most recent therapy (positive)

Tumor must be positive for CD20 by immunohistochemistry or flow cytometry after the most recent therapy.

Must have received: anti-cancer therapy

Relapsed/ refractory disease after at least one prior line of therapy. Relapse must have been confirmed histologically

Cannot have received: CD20-directed bispecific antibody (mosunetuzumab)

Exception: Prior exposure to 2 or less doses without evidence of resistance is allowed

Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies. Prior exposure to 2 or less doses without evidence of resistance is allowed

Cannot have received: antibody-drug conjugate containing monomethyl auristatin E (MMAE) (polatuzumab vedotin)

Exception: Prior exposure to 2 or less doses without evidence of resistance is allowed

Prior treatment with polatuzumab vedotin or with an antibody-drug conjugate containing monomethyl auristatin E (MMAE). Prior exposure to 2 or less doses without evidence of resistance is allowed

Cannot have received: allogeneic stem cell transplant

Exception: Allowed if >2 years prior to protocol therapy and stable off immunosuppressive agents for ≥ 2 months

Allogeneic stem cell transplant within 2 years prior to day 1 of protocol therapy, requires immunosuppression, or has evidence of active-versus-host-disease

Cannot have received: autologous stem cell transplant

Autologous stem cell transplant within 100 days prior to day 1 of protocol therapy

Cannot have received: CAR-T cell therapy

Chimeric antigen receptor (CAR)-T therapy within 30 days prior to day 1 of protocol therapy

Cannot have received: monoclonal antibody, radioimmunoconjugate or antineoplastic drug conjugate (ADC)

Prior use of any anti-lymphoma treatment with monoclonal antibody, radioimmunoconjugate or antineoplastic drug conjugate (ADC) within 4 weeks prior to day 1 of protocol therapy

Cannot have received: chemotherapeutic agent or other anti-cancer agent (investigational or otherwise)

Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to day 1 of protocol therapy

Cannot have received: radiotherapy

Exception: If patients have received radiotherapy within 4 weeks prior to day 1 of protocol therapy, must have at least one measurable lesion outside of the radiation field. Patients who have only one measurable lesion that was previously irradiated but subsequently progressed are eligible.

Treatment with radiotherapy within 2 weeks prior to day 1 of protocol therapy